Tymlos 80 MCG dose pen injectr 1.56ML
Ended Awarded
- Contract number
- SPE2DB25FXRT9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $2,335
Award facts
- Contract value 100% obligated
- $2,335.13 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was awarded a delivery order on September 3, 2025, by the Defense Logistics Agency (DLA) for TYMLOS 80 MCG Dose Pen Injector (1.56ML) with a ceiling value of $2.34K. This firm fixed-price delivery order, which has an ultimate completion date of September 4, 2025, carries no set-aside designation. The award will be performed at the contractor's facility in Park Ridge, Illinois. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program, a $500M vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products and medical supplies supporting Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain through its robust portfolio of delivery orders from the DLA. The company specializes in distributing branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to military and federal healthcare systems across the nation. The SPE2DB indefinite delivery contract framework allows the DLA to issue firm fixed-price delivery orders for specific pharmaceutical products as needed, ensuring efficient procurement of medical supplies for DoD healthcare operations. This particular delivery order for TYMLOS, a specialty injectable medication, exemplifies the company's role in providing specialized pharmaceutical products to support military medical readiness.
Quick answers
Who was awarded contract SPE2DB25FXRT9?
SPE2DB25FXRT9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 3, 2025.
How much is contract SPE2DB25FXRT9 worth?
The government has obligated $2,335 on SPE2DB25FXRT9.
Is contract SPE2DB25FXRT9 an order under another contract?
Yes. SPE2DB25FXRT9 is a delivery order under SPE2DB24D9131, an indefinite delivery contract.
Was contract SPE2DB25FXRT9 competed?
The extent of competition for SPE2DB25FXRT9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award